Page 3 - புற்றுநோய் மரபணு News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from புற்றுநோய் மரபணு. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In புற்றுநோய் மரபணு Today - Breaking & Trending Today

IU researchers identify how breast cancer cells evade immune attacks

IU researchers identify how breast cancer cells evade immune attacks
Researchers at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center have identified how breast cancer cells hide from immune cells to stay alive. The discovery could lead to better immunotherapy treatment for patients.
Xinna Zhang, PhD, and colleagues found that when breast cancer cells have an increased level of a protein called MAL2 on the cell surface, the cancer cells can evade immune attacks and continue to grow. The findings are published this month in
The Journal of Clinical Investigation and featured on the journal s cover.
The lead author of the study, Zhang is a member of the IU Simon Comprehensive Cancer Center and assistant professor of medical and molecular genetics at IU School of Medicine. ....

Xiongbin Lu , Xinna Zhang , Chi Zhang , Emily Henderson , Breast Cancer Research , Indiana University Precision Health Initiative , Iu School Of Medicine , Cancer Center Researcher , Vera Bradley Foundation Center , Bren Simon Comprehensive Cancer Center , Indiana University Melvin , Precision Health Initiative , Indiana University Grand Challenges Program , Iu Simon Comprehensive Cancer Center , Clinical Investigation , Comprehensive Cancer Center , Vera Bradley Foundation Professor , Breast Cancer Innovation , Cancer Genome , Cancer Center , Indiana University Precision Health , Both Xinna Zhang , Breast Cancer , Cancer Treatment , Immune System , சி ஜாங் ,

Lung-MAP translational discoveries shared at 2020 World Conference on Lung Cancer

E-Mail
WASHINGTON, DC - Investigators leading the Lung Cancer Master Protocol, or Lung-MAP trial, will present findings from three translational medicine studies at the 2020 World Conference on Lung Cancer, to be held online January 28-31, 2021.
The presentations will mark the first time that investigators share translational medicine insights from Lung-MAP, the first large-scale precision medicine trial in lung cancer backed by the National Cancer Institute (NCI), part of the National Institutes of Health, and the first major NCI trial to test multiple treatments, simultaneously, under one umbrella design. Since it launched in June 2014, the trial has tested 12 new lung cancer drugs. Lung-MAP has also amassed a scientifically valuable cache of data and biospecimens from 3,021 patients. ....

United States , Fred Hirsch , David Kozono , Philip Mack , Roy Herbst , Foundation Medicine , Yale University , Foundation For The National Institutes Of Health , National Clinical Trials Network , National Cancer Institute , Community Oncology Research Program , National Institutes Of Health , Phd Tisch Cancer Institute , Cancer Research Network , Friends Of Cancer Research , Phd Dana Farber Cancer Institute , Foundation Medicine Foundationone , Lung Cancer Master Protocol , Lung Cancer , National Institutes , International Association , Tisch Cancer Institute , Mount Sinai , Dana Farber Cancer Institute , Cancer Genome , Research Network ,

IU researchers discover how breast cancer cells hide from immune attack

E-Mail
INDIANAPOLIS Researchers at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center have identified how breast cancer cells hide from immune cells to stay alive. The discovery could lead to better immunotherapy treatment for patients.
Xinna Zhang, PhD, and colleagues found that when breast cancer cells have an increased level of a protein called MAL2 on the cell surface, the cancer cells can evade immune attacks and continue to grow. The findings are published this month in
The Journal of Clinical Investigation and featured on the journal s cover.
The lead author of the study, Zhang is a member of the IU Simon Comprehensive Cancer Center and assistant professor of medical and molecular genetics at IU School of Medicine. ....

United States , Yifan Sun , Tao Yu , Zhuolong Zhou , Jin Wang , Yuanzhang Fang , Haniyeh Eyvani , Lifei Wang , Tianhan Dong , Chi Zhang , Austynb Colter , Yujing Li , Xinna Zhang , Yunlong Liu , Georgee Sandusky , Xiongbin Lu , Edward Dong , Sha Cao , Bryanp Schneider , Breast Cancer Research , Indiana University Precision Health Initiative , Iu School Of Medicine , National Institutes Of Health , Vera Bradley Foundation Center , Bren Simon Comprehensive Cancer Center , Vera Bradley Foundation For Breast Cancer Research ,

New study can help determine effectiveness of chemotherapy in patients with bladder cancer

New study can help determine effectiveness of chemotherapy in patients with bladder cancer
In patients with bladder cancer, chemotherapy effectiveness is partially determined by the body s immune system response to the malignancy. This is the conclusion of research conducted by a team of scientists from Charité - Universitätsmedizin Berlin and the Berlin Institute of Health.
The findings, which have been published in
Science Translational Medicine, can be used to predict treatment success and may increase survival in patients with bladder cancer.
Bladder cancer is one of the ten most common types of cancer in Germany, and one of the five most common cancers in men. Nationwide, the disease affects approximately 30,000 people a year. The risk of cancer spreading (metastasizing) is particularly high once it invades the muscle layer inside the bladder wall. ....

Tino Vollmer , Michael Schm , Emily Henderson , Samir Sherif , Berlin Institute Of Health Center , Institute Of Medical Immunology , Berlin Center , Berlin Institute Of Health , Berlin Institute , Science Translational Medicine , Health Center , Regenerative Therapies , Medical Immunology , Advanced Therapies , Cancer Genome , Bladder Cancer , Immune System , டினோ வால்மர் , எமிலி ஹென்டர்சன் , அமீர் ஷெரிப் , பெர்லின் நிறுவனம் ஆஃப் ஆரோக்கியம் மையம் , நிறுவனம் ஆஃப் மருத்துவ நோயெதிர்ப்பு , பெர்லின் மையம் , பெர்லின் நிறுவனம் ஆஃப் ஆரோக்கியம் , பெர்லின் நிறுவனம் , அறிவியல் மொழிபெயர்ப்பு மருந்து ,

Bladder cancer -- When to use chemotherapy

E-Mail
IMAGE: The research team plans to study patients with bladder cancer and other cancers to establish whether cell therapy might be used to encourage and enhance the immune system s fight against.
view more
Credit: Photo: Hirscher/Charité
In patients with bladder cancer, chemotherapy effectiveness is partially determined by the body s immune system response to the malignancy. This is the conclusion of research conducted by a team of scientists from Charité - Universitätsmedizin Berlin and the Berlin Institute of Health. The findings, which have been published in
Science Translational Medicine , can be used to predict treatment success and may increase survival in patients with bladder cancer. ....

Tino Vollmer , Michael Schm , Samir Sherif , Berlin Institute Of Health Center , Institute Of Medical Immunology , Berlin Center , Berlin Institute Of Health , Berlin Institute , Science Translational , Health Center , Regenerative Therapies , Medical Immunology , Advanced Therapies , Cancer Genome , Transl Med , Medicine Health , Immunology Allergies Asthma , டினோ வால்மர் , அமீர் ஷெரிப் , பெர்லின் நிறுவனம் ஆஃப் ஆரோக்கியம் மையம் , நிறுவனம் ஆஃப் மருத்துவ நோயெதிர்ப்பு , பெர்லின் மையம் , பெர்லின் நிறுவனம் ஆஃப் ஆரோக்கியம் , பெர்லின் நிறுவனம் , அறிவியல் மொழிபெயர்ப்பு , ஆரோக்கியம் மையம் ,